Insider Selling: Crispr Therapeutics AG (CRSP) Major Shareholder Sells 158,718 Shares of Stock

Crispr Therapeutics AG (NASDAQ:CRSP) major shareholder Corp /De/ Celgene sold 158,718 shares of Crispr Therapeutics stock in a transaction on Monday, November 20th. The stock was sold at an average price of $19.02, for a total transaction of $3,018,816.36. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Major shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Corp /De/ Celgene also recently made the following trade(s):

  • On Friday, December 1st, Corp /De/ Celgene sold 87,991 shares of Crispr Therapeutics stock. The stock was sold at an average price of $19.10, for a total transaction of $1,680,628.10.
  • On Wednesday, November 29th, Corp /De/ Celgene sold 4,263 shares of Crispr Therapeutics stock. The stock was sold at an average price of $19.25, for a total transaction of $82,062.75.
  • On Monday, November 27th, Corp /De/ Celgene sold 27,990 shares of Crispr Therapeutics stock. The stock was sold at an average price of $19.75, for a total transaction of $552,802.50.
  • On Friday, November 24th, Corp /De/ Celgene sold 26,010 shares of Crispr Therapeutics stock. The stock was sold at an average price of $20.00, for a total transaction of $520,200.00.
  • On Wednesday, November 22nd, Corp /De/ Celgene sold 256,000 shares of Crispr Therapeutics stock. The shares were sold at an average price of $19.76, for a total transaction of $5,058,560.00.
  • On Friday, November 17th, Corp /De/ Celgene sold 51,282 shares of Crispr Therapeutics stock. The shares were sold at an average price of $18.44, for a total transaction of $945,640.08.
  • On Wednesday, November 15th, Corp /De/ Celgene sold 15,000 shares of Crispr Therapeutics stock. The shares were sold at an average price of $17.67, for a total transaction of $265,050.00.
  • On Monday, November 13th, Corp /De/ Celgene sold 65,093 shares of Crispr Therapeutics stock. The shares were sold at an average price of $17.76, for a total transaction of $1,156,051.68.
  • On Friday, November 10th, Corp /De/ Celgene sold 10,000 shares of Crispr Therapeutics stock. The shares were sold at an average price of $17.28, for a total transaction of $172,800.00.
  • On Wednesday, November 8th, Corp /De/ Celgene sold 16,875 shares of Crispr Therapeutics stock. The shares were sold at an average price of $18.06, for a total transaction of $304,762.50.

Shares of Crispr Therapeutics AG (NASDAQ CRSP) traded up $2.23 during midday trading on Friday, reaching $23.48. 848,356 shares of the company’s stock were exchanged, compared to its average volume of 362,318. The company has a market cap of $871.66, a P/E ratio of -17.79 and a beta of 5.70. Crispr Therapeutics AG has a one year low of $11.63 and a one year high of $25.00.

Crispr Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings results on Wednesday, November 8th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.02). The company had revenue of $2.39 million during the quarter, compared to the consensus estimate of $3.61 million. Crispr Therapeutics had a negative net margin of 466.58% and a negative return on equity of 38.42%. The business’s revenue was up 54.2% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($2.77) earnings per share. analysts forecast that Crispr Therapeutics AG will post -2.46 EPS for the current year.

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Granahan Investment Management Inc. MA increased its holdings in Crispr Therapeutics by 51.7% in the 3rd quarter. Granahan Investment Management Inc. MA now owns 263,746 shares of the company’s stock valued at $4,713,000 after acquiring an additional 89,839 shares during the last quarter. Allianz Asset Management GmbH bought a new stake in shares of Crispr Therapeutics in the 3rd quarter worth about $2,384,000. Credit Suisse AG bought a new stake in shares of Crispr Therapeutics in the 1st quarter worth about $1,742,000. Adams Street Partners LLC bought a new stake in shares of Crispr Therapeutics in the 3rd quarter worth about $1,019,000. Finally, Hershey Trust Co. bought a new stake in shares of Crispr Therapeutics in the 3rd quarter worth about $768,000. Institutional investors own 24.52% of the company’s stock.

A number of research analysts recently weighed in on CRSP shares. Barclays restated a “buy” rating and set a $29.00 target price on shares of Crispr Therapeutics in a research note on Friday, September 8th. Oppenheimer restated a “hold” rating on shares of Crispr Therapeutics in a research note on Thursday, December 21st. Cann restated a “hold” rating on shares of Crispr Therapeutics in a research note on Sunday, December 10th. BidaskClub cut shares of Crispr Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, December 2nd. Finally, SunTrust Banks reiterated a “hold” rating and issued a $16.00 price target on shares of Crispr Therapeutics in a report on Friday, November 10th. Four equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $22.38.

WARNING: “Insider Selling: Crispr Therapeutics AG (CRSP) Major Shareholder Sells 158,718 Shares of Stock” was originally reported by Week Herald and is the property of of Week Herald. If you are reading this news story on another domain, it was illegally stolen and republished in violation of United States & international copyright and trademark legislation. The original version of this news story can be viewed at https://weekherald.com/2017/12/30/corp-de-celgene-sells-158718-shares-of-crispr-therapeutics-ag-crsp-stock.html.

About Crispr Therapeutics

Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.

Insider Buying and Selling by Quarter for Crispr Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply